Pending Appeals
(FY10 to FY18: 9/30/10 to 11/30/17)

Note: FY17 pending changed from 13,034 to 13,044, and FY18 from 12,866 to 12,782 due to an internal end of FY18 Q1 audit.
Pendency of Decided Appeals in FY17 and FY18
(11/30/16 compared to 11/30/17)

<table>
<thead>
<tr>
<th>Technology</th>
<th>FY17</th>
<th>FY18</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bio / Pharma</td>
<td>22.8</td>
<td>19.4</td>
</tr>
<tr>
<td>Chemical</td>
<td>19.4</td>
<td>15.9</td>
</tr>
<tr>
<td>Electrical / Computer</td>
<td>16.2</td>
<td>16.2</td>
</tr>
<tr>
<td>Design</td>
<td>20.1</td>
<td>19.1</td>
</tr>
<tr>
<td>Mechanical / Business Method</td>
<td>32.4</td>
<td>26.9</td>
</tr>
<tr>
<td>Overall</td>
<td>20.7</td>
<td>16.2</td>
</tr>
</tbody>
</table>

Pendency is calculated as average months from Board receipt date to final decision.

*CRU (Central Reexamination Unit) includes ex parte reexams, inter partes reexams, supplemental examination reviews and reissues from all technologies.
*The Central Reexamination Unit includes ex parte reexams, inter partes reexams, supplemental examination reviews and reissues from all technologies.*
Appeal Outcomes in FY18
(FY18: 10/1/17 to 11/30/18)

- Affirmed: 58.3%
- Affirmed-in-Part: 11.2%
- Reversed: 28.1%
- Administrative and Panel Remands: 1.0%
- Dismissed: 1.4%
Interference Inventory
(FY08 to FY18: 9/30/08 to 11/30/17)